Navigation Links
TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
Date:8/8/2008

- Dr. Neil Kurtz Resigns as President and Chief Executive Officer; Evelyn

Graham Appointed Acting Chief Executive Officer -

LA JOLLA, Calif., Aug. 8 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Neil Kurtz, M.D., is resigning as President, Chief Executive Officer and a director of the company effective as of August 31, 2008. Dr. Kurtz is leaving TorreyPines to assume the role of President and Chief Executive Officer with a major healthcare services company. TorreyPines also named his replacement with the appointment of Evelyn Graham as acting Chief Executive Officer. Ms. Graham has been the company's Chief Operating Officer since 2006.

"We thank Neil for his leadership and many contributions to TorreyPines during his tenure as CEO," said Peter Davis, Ph.D., Chairman of the Board of Directors of TorreyPines.

Dr. Davis continued, "We are proud to announce the appointment of Ev as acting CEO. Her extensive drug development experience and detailed understanding of the company make her the perfect fit to lead TorreyPines as we continue to advance our programs through significant regulatory and clinical milestones."

"I look forward to continuing to work with our current management team in this new role to realize the full potential of our promising product candidates," said Ms. Graham. "We are currently preparing for our end of Phase II meeting with the FDA on September 29th during which we will discuss our proposed Phase III migraine program for tezampanel. In addition, we are continuing to advance NGX426, the oral version of tezampanel, having initiated a Phase I clinical trial to evaluate its analgesic effect. We anticipate announcing results from this Pha
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
2. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
5. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
6. Clinical Research Management gets contract for trials of therapeutics against infectious diseases
7. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
8. Nektar Therapeutics Announces Second Quarter 2008 Results
9. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
10. InteKrin Therapeutics Announces $20 Million Series C Financing
11. Transition Therapeutics Announces No Material Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Park Cities Pet Sitter is offering ... class starting Saturday, June 6th at 10:30am. The ... McCommas Blvd in Dallas, with a maximum of six dogs ... five weeks, with no class being held over the 4th ... , In this Intermediate-to-Advanced level class, dogs will solidify their ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced that ... & Vein Center! Dr. Gosin’s center is focused ... his mission to provide the highest quality care in a ... Jeffrey Gosin is Board Certified in Surgery and Vascular Surgery. ... Jefferson Medical College. He completed a General Surgery residency at ...
(Date:5/28/2015)... Lanham, Md. (PRWEB) May 28, 2015 ... Weekend Sweepstakes grand prize winner Robert Davis of Newark, ... Davis to congratulate him on winning the $10,000 sweepstakes ... winners from over 100,000 entries from around the country ... prize. The drawing took place on May 21 at ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital ... Sicilian economy by €132.5 million in expenditure in 2013, generated ... than €73 million by retaining patients who otherwise would have ... study by the Battelle Memorial Institute. At the same time, ... advanced health care management that is transforming Sicily into a ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... patients also leads to higher costs, study finds , ... acid reducer greatly increases the risk of pneumonia in ... found. , Researchers at Wake Forest University School of ... cardiothoracic surgery patients on breathing machines who were given ...
... WASHINGTON, Sept. 18 In response to the release ... Baucus, DMLR Chairman Stuart L. Weinstein, M.D. issued the following statement: ... is inadequate in addressing the serious problems caused by medical lawsuit ... care policy experts, opinion leaders, and patients all across the country ...
... , WEINER,S NEW YORK TIMES LETTER TODAY REFUTES ... Sept. 18 The Public Option is still viable as the House ... York Times) nor on ,life support, (ABC News)," says Robert Weiner, former Chief ... spokesman for the White House National Drug Policy Office. , , ...
... , , , ... Isotopes Inc. (OTC Bulletin Board: INIS) announces the successful conclusion ... and major shareholders. , , International Isotopes ... September 18, 2009 for just under $1 million. In ...
... LAKE SUCCESS, N.Y., Sept. 18 IPRO ... dissemination of tools and research findings aimed at improving ... United States. Under the Agency for Healthcare Research and ... task assignments to support accelerated dissemination of evidence-based products ...
... , CABOT, Vt., Sept. 18 Imagine if you ... Vegas without leaving your neighborhood! Well, that,s exactly what more than ... their way daily through Cabot Creamery Cooperative,s Vermont-to-Vegas Challenge. ... ) , , Participants competed online -- via ...
Cached Medicine News:Health News:Ulcer Preventative May Raise Pneumonia Risks 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Public Option Still Viable As House Set to Pass It -- Not 'Fading,' Says Robert Weiner, Former House Aging Committee Director 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 2Health News:International Isotopes Inc. Announces Successful Completion of a Private Placement 3Health News:IPRO Wins Knowledge Transfer/Implementation Federal Contract From AHRQ 2Health News:Cabot(R) Creamery Cooperative's Vermont-To-Vegas Virtual Challenge Ends On A Healthy Note 2Health News:Cabot(R) Creamery Cooperative's Vermont-To-Vegas Virtual Challenge Ends On A Healthy Note 3
(Date:5/28/2015)... DUBLIN , May 28, 2015 ... has announced the addition of the "United ... report to their offering.      ... medical adhesives in the United States ... through 2020 Medical device manufacturers ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... 28, 2015  Transportation Insight, a leading ... the SDCE100 Award for the second consecutive ... Executive magazine. Transportation Insight was chosen ... quantify and control supply chain costs associated ... market. Deploying Transportation Insight,s Enterprise Logistics solution ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3Lexicon To Present At The Jefferies 2015 Healthcare Conference 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 3Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 4
... LAKE GENEVA, Wis., Jan. 4, 2012 "My philosophy in ... so they can fully achieve their goals," mentions Robert ... Walworth Hospital and Medical Center in Lake Geneva, Wisconsin ... Dr. Paresi recently joined Mercy Health System with the ...
... PHOENIX, Jan. 4, 2012   Kedem Pharmaceuticals Inc. ... sublingual drug delivery is pleased to announce that it ... compliant formulation development company, Corealis Pharma, Inc. for the ... the Company,s second lead therapeutic drug. The KDM-1102 drug ...
Cached Medicine Technology:Fulfill New Year Resolutions with Cosmetic Surgery 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 2Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials 3
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... implant was conceived by Arthur C. Perry, ... comprehensive review of the literature on orbital ... back to 1885 (Mules 1885). This review, ... performance of contemporary implants, allowed Perry to ...
... Spheres for Enucleation and Evisceration. ... combine the structure of standard MEDPOR ... mixture. The Bioglass component, mixed throughout ... fibrovascular ingrowth into the MEDPOR PLUS ...
... ICL and the TORIC ICL are posterior ... STAARs proprietary collagen copolymer, the lens rests ... This unique material contains a small amount ... superior optical capability. The lens is gently ...
Medicine Products: